An underground economy for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.
Investigational Drug Gaining Traction Online
The experimental drug, which remains in clinical trials, is being advertised by online personalities for its alleged weight-reducing effects. Followers are encouraged to contact these accounts directly for source information, while also receiving discount codes.
Thriving Trade on Social Networks
Additionally, a robust trade exists on messaging services, where groups with numerous of participants share “before and after” images, injection guides and claims of next-day British shipping. Vendors market the drug there before redirecting buyers to WhatsApp for purchases.
Understanding The Experimental Drug
Retatrutide is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could assist individuals reduce up to 25% of their body weight. Referred to as the “triple G”, the substance is being promoted digitally as the next Ozempic.
Medical Experts Voice Worries
Nevertheless, physicians and chemists have warned that the sale of what remains an unapproved drug in the United Kingdom is worrisome and could result in users administering substances of uncertain source.
Several experts said the popularity for the experimental drug could be linked to the increasing cost of licensed weight loss products such as Mounjaro.
Regulatory Position and Enforcement
Marketing the unapproved drug on social media or messaging apps is illegal in the UK, as it is an unapproved drug that must not be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.
Several content creators attempt to circumvent the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and supply can still breach pharmaceutical, marketing, and customer laws, potentially leading to fines, prosecution or imprisonment.
Platform Reaction and Material Elimination
According to TikTok, the platform has taken down problematic content and banned related hashtags and query recommendations. The company said it was committed to maintaining the platform secure and investing in strengthening compliance measures.
Online Trading Activities
Investigations also discovered groups with up to nine thousand participants marketing retatrutide using Telegram's built-in discovery tool, which operates like a public directory. Entering “retatrutide” immediately brings up channels with numerous of members, populated with images of slimming results, positive testimonials and step-by-step instructions for preparing or injecting at home.
Within moments of entering one group, a vendor posted contact information, where most purchases take place. The seller sent an instruction manual and promised shipping within 48 hours. When asked whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a image of a supposed testing documentation. None asked about weight, medical conditions or previous experience.
Product Details and Pricing
Within these groups, messages display black plastic parcels with postal service labels, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”
Buyers can select between powder vials, prepared at home with purified liquid, or pre-filled pens usually priced at £160 for 20 milligrams. When asked how long a pen should last, sellers give conflicting responses ranging from a few weeks to “depends on your body”.
Platform Moderation and Safety Actions
A spokesperson for the messaging service stated it regularly moderated dangerous content on its platform including content that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.
Medical Professional Warnings
“People are administering substances they can’t verify. Even if the science behind retatrutide is valid, these online products may not include what they claim,” said Jason Murphy, the director of pharmacy at a pharmacy service.
A medical professional of Asda Online Doctor connected the increase in interest to current cost increases for approved weight-loss drugs such as Mounjaro. “With prices rising, individuals are using online platforms. But fake treatments are extremely risky. You cannot know what’s contained or whether the conditions they were produced in was clean,” she said.
Her team has previously encountered patients harmed by self-injection from unconfirmed sources. “We recognize the frustration, but buying from messaging apps or WhatsApp is gambling with your well-being,” said Wyllie. “These substances could be contaminated or improperly measured.”
Producer Statement
A representative from the pharmaceutical company said retatrutide was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Consequently at this time no one can sell [it] for personal consumption,” they said, adding that any item “falsely representing itself as a company investigational product not yet authorized … may subject patients to possibly serious health risks”.
